AZD7451 for Recurrent Gliomas

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 24% of the time (231 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-04-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularqtcsyndromeor equalequal to
  Phrases that lowered it: patientssubjectweeksbloodbleeding
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 11.3% (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Maximum age: 100 (lowers risk) · Who can join
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Disease area, neurology: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 297 (raises risk) · Sponsor's track record
• Number of arms: not given (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: not given (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Sponsor's past trials: 542 (lowers risk) · Sponsor's track record
• Keywords listed: 8 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• AZD8055 for Adults With Recurrent Gliomas NCT01316809 · started 2011 · scored riskier than 54% of active trials completed
• mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme NCT02619864 · started 2016 · scored riskier than 42% of active trials completed
• AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas NCT02831257 · started 2016 · scored riskier than 97% of active trials completed
• Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... NCT01229150 · started 2010 · scored riskier than 89% of active trials completed
• CISPLATIN + AZD-1775 In Breast Cancer NCT03012477 · started 2017 · scored riskier than 94% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.